Recently, Tianjin Pharmaceutical Group's subsidiary, Tianjin Pharmaceutical Peace, received the Drug Registration Certificate for Butorphanol Tartrate Injection issued by the National Medical Products Administration.

It is understood that the main ingredient of this drug is butorphanol tartrate, which belongs to the Class II psychotropic drugs stipulated in the "Regulations on the Administration of Narcotic Drugs and Psychotropic Substances" of China. Its indications are for the treatment of various types of cancer pain and postoperative pain. This approval will further enrich Tianjin Pharmaceutical Group's product pipeline in the field of narcotic and psychotropic drugs, improve the company's formulation product group, and will have a positive impact on the company's operating performance.

Tianjin Pharmaceutical Group has been expanding its product categories. The company focuses on key areas such as ophthalmology, dermatology, emergency care, respiratory, autoimmune diseases, and psychotropic drugs, strengthening its insights, pipeline planning, and project initiation to improve its pipeline layout capabilities and explore key potential products.

Articles: Board Office of Tianjin Pharmaceutical Group Co., Ltd., China Securities Journal (China Securities Network)